Home>Topics>Companies>Bayer AG

Bayer AG

  1. All
  2. Commentary
  3. Headlines
  1. Bayer buys rights to Isis Pharma's anti-clotting drug


    Mon, 4 May 2015

    FRANKFURT, May 4 (Reuters) - German drugmaker Bayer secured the rights to an experimental anti-blood-clotting drug in a deal with California-based Isis Pharmaceuticals to bolster its cardiovascular business led by blockbuster pill Xarelto.

  2. BRIEF- Bayer healthcare sees adj Q2 sales at least at Q1 level


    Thu, 30 Apr 2015

    * Says healthcare now expects sales to rise to over eur 24 billion (previously: approximately eur 23 billion)

  3. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019


    Tue, 21 Apr 2015

    EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche ..... Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other ..... Allergan Inc. - Ampio Pharmaceuticals Inc. - Antisense Therapeutics

  4. Complexities of Eye Care Drive Strong Moats


    Fri, 6 Mar 2015

    of three segments: pharmaceuticals , consumer products ..... diseases. Eye-Care Pharmaceuticals Anti-VEGF treatments ..... Regeneron 's REGN and Bayer 's BAYRY Eylea and ..... Other eye-care pharmaceuticals include treatments

  5. Global Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020


    Fri, 27 Feb 2015

    the prominent players in the global home healthcare market that have been profiled in the report include 3M Health Care, Bayer AG , Abbott Laboratories, Cardinal Health, Inc., GE Healthcare, Johnson & Johnson Services, Inc., Gentiva Health Services

  6. Salivary Gland Cancer - Pipeline Review, H2 2014


    Wed, 21 Jan 2015

    Companies Involved in Therapeutics Development AstraZeneca PLC Bayer AG Incuron, LLC Novartis AG Otsuka Holdings Co., Ltd. Salivary ..... AstraZeneca PLC, H2 2014 Salivary Gland Cancer - Pipeline by Bayer AG , H2 2014 Salivary Gland Cancer - Pipeline by Incuron

  7. Bayer explores possible sale of diabetes device unit -Bloomberg


    Mon, 24 Nov 2014

    Nov 24 (Reuters) - Germany-based drugmaker Bayer AG is considering the sale of its diabetes device business, Bloomberg reported, citing sources.

  8. Bayer Posts Strong 3Q Led by Pharmaceuticals ; Break Off of No Moat Material Science Group on Track


    Thu, 30 Oct 2014

    by the drug division, Bayer reported strong third ..... expect the strong growth in pharmaceuticals sales (up 10% year over ..... growth as well. However, Bayer needs to accelerate its ..... consumer group. We believe Bayer can leverage is global

  9. From Barron’s, August 25, 2014 (Part 1)


    Sat, 23 Aug 2014

    emerging-markets, reduced government budgets and increased R&D costs. For those wanting to buy, Novartis [ NVS ] and Bayer [ BAYN .ge/ BAYRY ] are attractive. Pg M7, Asia: Korean steel Posco [5490.sk/ PKX ] and Chinese car maker BYD [1211

  10. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns


    Thu, 26 Jun 2014

    order to acquire Cadence Pharmaceuticals . While the deal gives ..... example, we only downgraded Bayer 's BAYRY "> BAYRY issuer ..... will significantly expand Bayer 's already well-positioned ..... material science toward Bayer 's health-care operations

« Prev12345Next »
Content Partners